



Year: 2014

Alveolar macrophages are the main target cells in feline calicivirus-associated pneumonia

Monné Rodriguez, J M ; Soare, T ; Malbon, A ; Blundell, R ; Papoula-Pereira, R ; Leeming, G ; Köhler, K ; Kipar, A

Abstract: Feline calicivirus (FCV) is a pathogen of felids and one of the most common causative agents of feline upper respiratory disease (URD). Reports of natural FCV pneumonia in the course of respiratory tract infections are sparse. Therefore, knowledge on the pathogenesis of FCV-induced lung lesions comes only from experimental studies. The aim of the present study was to assess the type and extent of pulmonary involvement in natural respiratory FCV infections of domestic cats and to identify the viral target cells in the lung. For this purpose, histology, immunohistochemistry and RNA-in situ hybridisation for FCV and relevant cell markers were performed on diagnostic post-mortem specimens collected after fatal URD, virulent systemic FCV or other conditions. All groups of cats exhibited similar acute pathological changes, dominated by multifocal desquamation of activated alveolar macrophages (AM) and occasional type II pneumocytes with fibrin exudation, consistent with diffuse alveolar damage (DAD). In fatal cases, this was generally seen without evidence of epithelial regeneration. In cats without clinical respiratory signs, type II pneumocyte hyperplasia was present alongside the other changes, consistent with the post-damage proliferative phase of DAD. FCV infected and replicated in AM and, to a lesser extent, type II pneumocytes. This study shows that lung involvement is an infrequent but important feature of FCV-induced URD. AM are the main viral target cell and pulmonary replication site, and their infection is associated with desquamation and activation, as well as death via apoptosis.

DOI: <https://doi.org/10.1016/j.tvjl.2014.04.022>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-96949>

Journal Article

Accepted Version

Originally published at:

Monné Rodriguez, J M; Soare, T; Malbon, A; Blundell, R; Papoula-Pereira, R; Leeming, G; Köhler, K; Kipar, A (2014). Alveolar macrophages are the main target cells in feline calicivirus-associated pneumonia. *Veterinary Journal*, 201(2):156-165.

DOI: <https://doi.org/10.1016/j.tvjl.2014.04.022>

Manuscript Number: YTVJL-D-13-01119R1

Title: Alveolar macrophages are the main target cells in feline calicivirus-associated pneumonia

Article Type: Feline Infectious Diseases Special Issue

Keywords: Feline calicivirus; Pulmonary infection; Alveolar macrophages; Immunohistochemistry; RNA-in situ hybridisation

Corresponding Author: Prof. Anja Kipar, Dr.med.vet.habil.

Corresponding Author's Institution: University of Liverpool

First Author: Josep M Monné Rodriguez, Veterinarian

Order of Authors: Josep M Monné Rodriguez, Veterinarian; Teodore Soare, PhD; Alexandra Malbon, BVSc, BSc; Richard Blundell, BVetMed MSc PhD Dipl.ECVP; Rita I Papoula-Pereira, DVM PhD; Gail Leeming, BVetMed MPhil PhD FRCPath ; Kernt Koehler, Dr.med.vet.; Anja Kipar, Dr.med.vet.habil.

Abstract: Feline calicivirus (FCV) is a pathogen of felids and one of the most common causative agents of feline upper respiratory disease (URD). Reports of natural FCV pneumonia in the course of respiratory tract infections are sparse. Therefore, knowledge on the pathogenesis of FCV-induced lung lesions comes only from experimental studies. The aim of the present study was to assess the type and extent of pulmonary involvement in natural respiratory FCV infections of domestic cats and to identify the viral target cells in the lung. For this purpose, histology, immunohistochemistry and RNA-in situ hybridisation for FCV and relevant cell markers were **employed in** diagnostic post-mortem specimens collected after fatal URD, virulent systemic FCV or other conditions. All groups of cats exhibited similar acute pathological changes, dominated by multifocal desquamation of activated alveolar macrophages (AM) and occasional type II pneumocytes with fibrin exudation, consistent with diffuse alveolar damage (DAD). In fatal cases, this was generally seen without evidence of epithelial regeneration. In cats without clinical respiratory signs, type II pneumocyte hyperplasia was present alongside the other changes, consistent with the post-damage proliferative phase of DAD. FCV infected and **replicate** in AM and, to a lesser extent, type II pneumocytes. This study shows that lung involvement is an infrequent but important feature of FCV-induced URD. AM are the main viral target cell and pulmonary replication site, and their infection is associated with desquamation and activation, as well as death via apoptosis.

1 Original Article

2

3 **Alveolar macrophages are the main target cells in feline calicivirus-associated**
4 **pneumonia**

5

6

7 J.M. Monné Rodriguez ^a, T. Soare ^{a,b}, A. Malbon ^a, R. Blundell ^{a,c}, R. Papoula-Pereira ^{a,c}, G.
8 Leeming ^{a,c}, K. Köhler ^d, A. Kipar ^{a,c,e,*}

9

10 ^a *Veterinary Pathology, School of Veterinary Science, University of Liverpool, Leahurst*
11 *Campus, Chester High Road, Neston CH64 7TE, UK*

12 ^b *University of Agricultural Sciences and Veterinary Medicine, Splaiul Independentei 105,*
13 *050097 Bucharest, Romania*

14 ^c *Department of Infection Biology, Institute of Global Health, University of Liverpool,*
15 *Liverpool Science Park IC2, 146 Brownlow Hill, Liverpool L3 5RF, UK*

16 ^d *Institute of Veterinary Pathology, Faculty of Veterinary Medicine, University of Giessen,*
17 *Frankfurter Strasse 96, 35393 Giessen, Germany*

18 ^e *Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Winterthurer*
19 *Strasse 268, 8057 Zurich, Switzerland*

20

21

22

23

24 * Corresponding author. Tel.: +41 44 6358552.

25 E-mail address: akipar@liverpool.ac.uk (A. Kipar).

26 **Abstract**

27 Feline calicivirus (FCV) is a pathogen of felids and one of the most common causative
28 agents of feline upper respiratory disease (URD). Reports of natural FCV pneumonia in the
29 course of respiratory tract infections are sparse. Therefore, knowledge on the pathogenesis of
30 FCV-induced lung lesions comes only from experimental studies. The aim of the present
31 study was to assess the type and extent of pulmonary involvement in natural respiratory FCV
32 infections of domestic cats and to identify the viral target cells in the lung. For this purpose,
33 histology, immunohistochemistry and RNA-in situ hybridisation for FCV and relevant cell
34 markers were employed in diagnostic post-mortem specimens collected after fatal URD,
35 virulent systemic FCV or other conditions. All groups of cats exhibited similar acute
36 pathological changes, dominated by multifocal desquamation of activated alveolar
37 macrophages (AM) and occasional type II pneumocytes with fibrin exudation, consistent with
38 diffuse alveolar damage (DAD). In fatal cases, this was generally seen without evidence of
39 epithelial regeneration. In cats without clinical respiratory signs, type II pneumocyte
40 hyperplasia was present alongside the other changes, consistent with the post-damage
41 proliferative phase of DAD. FCV infected and replicate in AM and, to a lesser extent, type II
42 pneumocytes. This study shows that lung involvement is an infrequent but important feature
43 of FCV-induced URD. AM are the main viral target cell and pulmonary replication site, and
44 their infection is associated with desquamation and activation, as well as death via apoptosis.

45

46 *Keywords:* Feline calicivirus; Pulmonary infection; Alveolar macrophages;

47 Immunohistochemistry; RNA-in situ hybridisation

48

49 **Introduction**

50 Feline calicivirus (FCV) is one of the most common causative infectious agents of
51 feline upper respiratory disease (URD; Bannasch and Foley, 2005; Di Martino et al., 2007;
52 Gaskell et al., 2012). URD is widespread and common in cats and presents with a variety of
53 clinical signs, including conjunctivitis, rhinitis, oral ulcers and, occasionally, pneumonia
54 (Hurley and Sykes, 2003; Gaskell et al., 2006; Radford et al., 2007; Pesavento et al., 2008;
55 Radford et al., 2009). The mortality rate is usually low, but occasionally kittens develop fatal
56 pneumonia (Love and Baker, 1972; Turnquist and Ostlund, 1997).

57

58 FCV is a member of the Caliciviridae, which possess a non-enveloped, positive-sense,
59 single-stranded RNA genome of approximately 7.5 kb (Clarke and Lambden, 1997). The
60 virus exhibits high genetic variability and there are a variety of natural strains (Radford et al.,
61 2003) with variable cell tropism, pathogenesis and virulence, resulting in different clinical
62 manifestations, such as self limiting URD, lameness due to acute synovitis (Dawson et al.,
63 1994) and systemic disease caused by highly virulent strains, so-called virulent systemic
64 (VS)-FCV (Hurley and Sykes, 2003; Radford et al., 2007; Pesavento et al., 2008). The genetic
65 diversity of FCV is a consequence of changes in the hypervariable C and E regions that
66 encode part of the capsid proteins involved in the generation of neutralising antibodies
67 (Radford et al., 1999; Geissler et al., 2002). Animals develop a protective immune response
68 against FCV (Kahn et al., 1975; Kahn and Hoover, 1976; Scott, 1977); however, continual
69 genomic changes in the virus can lead to reinfections with different strains or closely related
70 variants of the same strain, despite previous infection episodes (Johnson, 1992; Radford et al.,
71 2003; Coyne et al., 2006b, 2007). Due to the genetic instability of FCV, effective disease
72 prophylaxis has remained challenging (Radford et al., 1997) and, after years of vaccination
73 programmes, infection is still widespread, leading to the search for new heterologous vaccines

74 that can protect against more than one strain (Poulet et al., 2005; Radford et al., 2006).
75 Moreover, in 1998, new highly virulent VS-FCV strains emerged. The first VS-FCV cases
76 were observed in California (Pedersen et al., 2000), but further outbreaks have subsequently
77 been reported from the USA (Schorr-Evans et al., 2003; Hurley et al., 2004; Pesavento et al.,
78 2004) and, more recently, Europe (Coyne et al., 2006a; Schulz et al., 2011; Battilani et al.,
79 2013; Velasco et al., 2013). The most frequent clinical signs are cutaneous oedema (mainly on
80 the head and limbs), ulceration of the skin and mucosa, predominantly affecting the oral
81 cavity, nares, pinnae and footpads, and clinical signs due to multi-organ necrosis, most
82 commonly affecting the liver, but occasionally also the spleen, pancreas or lungs (Pedersen et
83 al., 2000; Hurley and Sykes, 2003; Coyne et al., 2006a; Radford et al., 2007; Pesavento et al.,
84 2008; Radford et al., 2009).

85

86 Reports of natural FCV pneumonia are sparse and our understanding of the
87 pathogenesis of FCV-induced lung lesions is from experimental studies only. These used high
88 doses (up to 2×10^4 median tissue culture infective dose) of virus propagated in tissue culture
89 in an aerosol for the intranasal infection of kittens and young cats, which often resulted in
90 pulmonary involvement (Holzinger and Kahn, 1970; Kahn and Gillespie, 1971; Hoover and
91 Kahn, 1973, 1975; Love, 1975; Langloss et al., 1978a). The development and type of lung
92 lesions was generally similar; after an initial phase of pneumocyte injury with exudation and
93 neutrophil infiltration, proliferation of type II pneumocytes and desquamation of alveolar
94 macrophages (AM) into the alveolar lumen was observed. Virus was detected by
95 immunofluorescence in pneumocytes and AM (Holzinger and Kahn, 1970; Kahn and
96 Gillespie, 1971). Some authors suggested a correlation between the type of virus inoculum
97 and the clinical signs (Love, 1975; Ormerod et al., 1979), and it has since been accepted that
98 the experimental studies overemphasise the relevance of FCV-associated pneumonia, since

99 natural infection mainly occurs via the oronasal route (Radford et al., 2007; Gaskell et al.,
100 2012). However, other authors have suggested that severe pneumonia might not be rare in
101 naturally infected cats (Pesavento et al., 2008).

102

103 Definitive reports of pneumonia as a complication of severe, naturally acquired FCV-
104 associated respiratory disease are very rare (Love and Baker, 1972; Turnquist and Ostlund,
105 1997). Furthermore, attempts to demonstrate the virus in the lungs to assess whether FCV or
106 bacteria, such as *Bordetella bronchiseptica*, were the relevant pulmonary pathogen, have not
107 been made (Turnquist and Ostlund, 1997). This study, which was initiated after acute
108 pneumonia and FCV infection had been diagnosed post-mortem in a number of cats with
109 URD, aimed to assess the type and extent of pulmonary involvement in natural respiratory
110 FCV infections of domestic cats, and to identify the viral target cells in the lung. For this
111 purpose, histopathology, immunohistochemistry (IH) and RNA-in situ hybridisation were
112 employed on post-mortem specimens from cats with fatal URD, VS-FCV or other conditions.

113

114 **Materials and methods**

115 *Animals and tissues*

116 The study was performed on **specimens from** cats from Germany, the UK, Finland, Italy
117 and Spain that had undergone full diagnostic post-mortem examinations. Tissue specimens
118 had been collected for histological examination and, in some cases, for virological and
119 bacteriological examinations (Tables 1-4). Four groups were included. Group 1 comprised
120 eight cats with clinical histories of URD and pneumonia. FCV was isolated from the lungs by
121 virus culture and involvement of FCV in the pneumonia was confirmed by IH. Group 2
122 comprised five cats with URD and pneumonia. Virus culture was not performed, but FCV
123 involvement was confirmed by IH. Group 3 comprised two cats without URD. These had
124 been euthanased because of feline parvovirus infection, but exhibited histopathological

125 findings consistent with FCV pneumonia, confirmed by FCV IH. Group 4 comprised four cats
126 with VS-FCV; pulmonary specimens from these cats were examined by IH for the presence
127 and distribution of FCV. Most of the cats in group 4 have since been reported as confirmed
128 cases of VS-FCV in the UK (Coyne et al., 2006a), Italy (Battilani et al., 2013) and Spain
129 (Velasco et al., 2013).

130

131 All lung tissue specimens were fixed in 10% non-buffered formalin for 24-72 h,
132 followed by trimming and routine paraffin wax embedding. Specimens of tongue, larynx or
133 nose were also examined when they showed gross lesions associated with URD. Other
134 tissues/organs (spleen, liver, kidney, intestine, brain) were processed for histological
135 examination, to identify or exclude any concurrent disease.

136

137 *Histology*

138 Sections (3-5 µm thick) were prepared and stained with haematoxylin and eosin for
139 histopathological examination. Consecutive sections were prepared and mounted on polysine
140 slides (VWR International Eurolab S.L) for IH and RNA-in situ hybridisation.

141

142 *Immunohistochemistry*

143 IH was used to demonstrate viral antigen (FCV and, in most specimens from groups 1 and
144 2, FHV, to exclude FHV infection of the lung and to confirm the involvement of FHV in one
145 case of ulcerative glossitis), type II pneumocytes (surfactant protein, SP-C, positive), AM
146 (CD18 positive), apoptotic cells (cleaved caspase-3 positive) and the functional marker matrix
147 metalloproteinase (MMP)-9 in the lungs. FCV antigen expression was also assessed in other
148 lesions consistent with URD to confirm aetiology and in other organ specimens from cats
149 with VS-FCV (Coyne et al., 2006a; Battilani et al., 2013).

150

151 The peroxidase anti-peroxidase (PAP), avidin biotin complex peroxidase (ABC) and
152 horseradish peroxidase (HRP) methods were applied, as previously described (Kipar et al.,
153 2005; Coyne et al., 2006a; Leeming et al., 2006). All antibodies, antigen retrieval and
154 detection methods are listed in Table 5. The two antibodies against FCV were both used on
155 consecutive sections of the same case (cats in group 1; with similar staining results), or were
156 used alternatively.

157

158 A formalin-fixed and paraffin-embedded cell pellet prepared from an FCV infected
159 tissue culture (see below), and sections prepared from a case of glossitis with strong
160 expression of FCV antigen, a similarly prepared FHV-infected cell pellet and a specimen
161 from a cat with necrotising rhinitis with strong FHV antigen expression served as positive
162 controls for the virus IH; a specimen with granulomatous dermatitis was used as control for
163 the functional markers. Negative controls were represented by consecutive sections in which
164 the primary antibody was omitted or replaced by a non-reacting polyclonal antibody against
165 *Toxoplasma gondii* or a mouse monoclonal antibody against canine distemper virus.

166

167 *RNA-in situ hybridisation*

168 *Virus cultivation, RNA extraction and cDNA preparation* - The FCV strain F9 (Carter et
169 al., 1992) was cultured in feline embryo A (FEA) cells using standard protocols (Povey and
170 Johnson, 1971; Carter et al., 1992) and a multiplicity of infection of 0.001 plaque forming
171 units/cell in a volume of 5 mL growth medium. RNA was extracted and reverse transcribed
172 into cDNA, as previously described (Coyne et al., 2007).

173

174 *Preparation of riboprobes* - Nine full genome FCV nucleotide sequences were retrieved
175 from GenBank¹ (accession numbers AY560115, AY560113, M86379, D31836, AF479590,
176 L40021, AF109465, DQ424892 and AY560117) and aligned using CLUSTAL W alignment
177 editor MEGA version 4 (Tamura et al., 2007). A pair of primers, forward and reverse, were
178 designed to amplify a relatively conserved region of ORF1 from residues 2420 to 2550 of the
179 FCV genome (FCV 2420-fw: 5'-GAACTACCCGCCAATCAACATGTGGTAAC-3' and
180 FCV 2550-rev: 3'-GGGACAGTTAGCACRTCRTATGCGGC-5'), to produce an amplicon of
181 130 base pairs (A.D. Radford, personal communication). The PCR product amplified from the
182 viral cDNA was cloned into a plasmid vector (pCRII, Invitrogen, Life Technologies), using a
183 commercially available kit (TOPO TA cloning kit, Invitrogen), and a digoxigenin (DIG)-
184 labelled probe was generated by in vitro transcription, as previously described (Hughes et al.,
185 2011), using a DIG RNA labelling kit (Roche Diagnostics) to generate sense and anti-sense
186 riboprobes. The correct concentration of the probe for use on tissue sections was determined
187 empirically using dot blots and RNA-ISH on formalin-fixed, paraffin-embedded pelleted cells
188 from FCV-infected cell cultures.

189
190 *RNA-in situ hybridisation* - RNA-ISH was performed according to a previously
191 published protocol (Kipar et al., 2005). After deparaffinisation, sections were digested with
192 proteinase K (1 µg/mL, Roche Diagnostics) for 25 min to expose the target RNA, followed by
193 post-fixation, acetylation and prehybridisation steps. Hybridisation was performed by
194 incubation of slides at 37 °C for 15-18 h; the hybridisation mix contained either the anti-sense
195 probe (for the detection of positive strand viral RNA) or the sense probe (for the detection of
196 negative strand, replicative intermediate stage viral RNA), respectively. After post-
197 hybridisation washing, probe binding was visualised with alkaline phosphatase-coupled anti-

¹ See: <https://www.ncbi.nlm.nih.gov/genbank/>.

198 DIG antibody (anti-DIG-AP FAb fragments; Roche Diagnostics) and nitroblue tetrazolium
199 chloride (NBT)/5-bromo-4-chloro-3-indolylphosphate (BCIP; SigmaFast BCIP/NBT; Sigma-
200 Aldrich). Sections were counterstained for 10 s with Papanicolaou's haematoxylin (Merck
201 KGaA). Sections that were incubated with the hybridisation mix alone served as negative
202 controls.

203

204 **Results**

205 *Histopathology associated with feline calicivirus infection of the lungs*

206 Pulmonary specimens from cats with URD and histological evidence of pneumonia,
207 from which FCV was isolated in culture (group 1), served to identify the type of pathological
208 changes induced in the lungs after natural FCV infection. Subsequent examination of the
209 lungs of all other groups (group 2: URD with pneumonia, confirmed by FCV IH alone; group
210 3: no URD, but pulmonary changes similar to groups 1 and 2; group 4: VS-FCV) confirmed a
211 range of key histopathological features that were consistently observed in all cats.

212

213 The main finding was multifocal desquamation of large, round, often vacuolated
214 mononuclear cells into the alveolar lumen, generally in association with fibrin exudation (Fig.
215 1). The extent of this feature varied, both with regard to the number and distribution of
216 affected alveoli and the number of desquamated cells in individual alveoli. The desquamated
217 cells were mostly AM, confirmed by their consistent, strong CD18 expression (Fig. 2A).
218 Among these were occasional type II pneumocytes, which were identified by their expression
219 of SP-C (Fig. 2B). The morphology of type II pneumocytes (large, cuboidal cells) often
220 suggested an activated state, which was also confirmed by IH, since both these cells and AM
221 expressed MMP-9 (Fig. 2C). A variable proportion of the desquamated cells were undergoing
222 apoptosis, exemplified by the typical morphology and the expression of cleaved caspase-3

223 (Fig. 2D). In areas with extensive alveolar fibrin exudation, fibrin was also found on the
224 pleura. Occasionally, erythrocyte extravasation into the alveolar lumen was also observed
225 (Fig. 1B). In rare cases (groups 2 and 3, $n = 1$ each), mild to focally moderate type II
226 pneumocyte hyperplasia was observed (Fig. 1C). FCV antigen was expressed by variable
227 numbers of desquamated AM, which were often apoptotic (Fig. 3). Occasional type II
228 pneumocytes also expressed viral antigen (Fig. 3B, 3C inset).

229

230 In all eight cats in group 1, pulmonary changes were acute and locally extensive to
231 diffuse, without evidence of alveolar epithelial cell regeneration or substantial interstitial
232 leucocyte infiltration. Apart from one case (cat 1.5), all cats had alveolar fibrin exudation
233 along with desquamation of AM and type II pneumocytes in the lungs (Table 1). When tested,
234 FCV antigen was also demonstrated in URD lesions, i.e. ulcerative glossitis (cats 1.4 and 2.3)
235 and rhinitis (cat 2.6). Interestingly, cat 1.5 exhibited FCV and FHV co-infection in the
236 ulcerative glossitis, but only FCV was detected in the lung by both virus isolation and IH.

237

238 Bacteriology had been performed on all cats in group 1. Pulmonary bacterial infection
239 with *Pasteurella multocida* was identified in two cats (cats 1.4 and 1.7); in one case (cat 1.4)
240 there was a co-infection with γ -haemolytic *Streptococcus* sp. Septicaemia was diagnosed in
241 six cats, either with a mixed population of bacterial isolates (cats 1.3-1.6) or haemolytic
242 *Escherichia coli* (cats 1.1 and 1.8). One cat (cat 1.4) also had feline parvovirus enteritis,
243 confirmed by IH.

244

245 Group 2 comprised six cats with URD and pulmonary changes that were identical to
246 those in group 1. In these cases, FCV involvement was confirmed only by IH for FCV
247 antigen. In most cases, IH for FHV had been performed concurrently to confirm that FHV

248 was not involved (Table 2). In group 2, all but one case (cat 2.4) had alveolar fibrin exudation.
249 In one case (cat 2.5), the presence of mild focal type II pneumocyte hyperplasia and moderate
250 interstitial macrophage infiltration indicated a slightly longer course of disease. FCV antigen
251 was also present in URD lesions, i.e. laryngitis (cat 2.2), glossitis (cat 2.3), and rhinitis (cat
252 2.6). In one case (cat 2.1), an unidentified *Mycoplasma* sp. was isolated from the lungs. In the
253 remaining cases, bacteriological examination either was not performed or did not yield any
254 predominant bacterial isolates.

255

256 Group 3 was represented by two cats that had been euthanased due to feline parvovirus
257 enteritis, without clinical or gross pathological signs of URD or pneumonia. Both exhibited
258 histopathological changes in the lung that were similar to those observed in groups 1 and 2,
259 the only difference being that they were generally only mild and patchy in the group 3 cats.
260 However, the presence of moderate multifocal type II pneumocyte hyperplasia (Fig. 1C)
261 indicated a longer course of disease than in most cats from groups 1 and 2 (Table 3).

262

263 In all cats in group 4, VS-FCV was confirmed by the presence of typical necrotising
264 organ lesions and, with the exception of cat 4.3, the isolation of FCV from oropharyngeal
265 swabs or organs, PCR and sequencing (Coyne et al., 2006a; Battilani et al., 2013; Velasco et
266 al., 2013). The lungs were always involved and showed typical multifocal desquamation of
267 AM and occasional type II pneumocytes (Table 4). One cat (cat 4.3) had marked alveolar
268 fibrin exudation and intense desquamation of cells into the alveolar lumina. A few
269 bronchioles had focal loss of the respiratory epithelium and apoptosis of sloughing epithelial
270 cells (Fig. 1D). These cells expressed FCV antigen, similar to the desquamated cells in the
271 alveolar lumina (Fig. 3D).

272

273 *Feline calicivirus replication in the lung*

274 Alongside the demonstration of viral antigen by IH, FCV was demonstrated by RNA-ISH
275 (positive strand viral RNA; binding to anti-sense riboprobe) within desquamated AM (Fig.
276 4A, B). RNA-ISH using the sense probe yielded a positive signal in a small proportion of
277 these cells, confirming that the virus was not only taken up by the cells, but replicated in the
278 infected cells (Fig. 4A). Viral replication was also demonstrated in activated and hyperplastic
279 type II pneumocytes (Fig. 4B, C). In the VS-FCV case with infection of bronchiolar
280 respiratory epithelial cells, viral replication was also demonstrated in these cells (Fig. 4D).

281

282 **Discussion**

283 This retrospective study aimed to provide insight into the relevance and effect of FCV
284 in the lungs of naturally infected cats. For this purpose, we initially examined a group of cats
285 with URD that had been euthanased, underwent post-mortem examination and had
286 histological evidence of acute pneumonia in which FCV was suggested to play a role, since
287 the virus was isolated from the lungs. The key histological feature in these lungs was severe
288 acute diffuse alveolar damage (DAD), represented by extensive multifocal to diffuse
289 desquamation of AM (CD18 positive) and occasional type II pneumocytes (SP-C positive;
290 Mulugeta and Beers, 2006) that accumulated in the alveolar lumen, together with variable
291 amounts of fibrin and occasional erythrocytes. IH demonstrated FCV antigen in the
292 desquamated cells, providing strong evidence that the virus played a pathogenic role in the
293 lungs. The apparent lack of alveolar epithelial regeneration and/or inflammatory cell
294 recruitment suggests that the cats died or were euthanased due to virus-induced acute DAD, as
295 a fatal complication of severe FCV-induced URD.

296

297 We also included cats that had presented with URD and identical acute pulmonary
298 changes in which a virological examination had not been undertaken. Based on the results of
299 the first group, we considered IH demonstration of FCV in the desquamated cells to be
300 diagnostic for acute FCV-associated pneumonia. Subsequent application of the histological
301 criteria identified another two cases of suspected FCV-induced lung lesions, in which the
302 involvement of FCV was confirmed by IH. Interestingly, both cats also had feline parvovirus
303 enteritis. Considering that infection with feline parvovirus not only induces enteritis, but also
304 marked leucopenia and immunosuppression (Truyen et al., 2009), it is possible that the
305 observed, albeit mild, pneumonia was a consequence of viral recrudescence from sites of
306 persistence, such as the tonsils, due to immunosuppression (Dick et al., 1989; Radford et al.,
307 2007; Gaskell et al., 2012). Also, in both cats, there was evidence of a slightly longer time
308 course of disease, since both exhibited multifocal type II pneumocyte hyperplasia, a feature
309 generally observed 6-7 days after pneumocyte damage (Myers et al., 1993; Caswell and
310 Williams, 2007). This has also been observed 7-14 days after experimental infection of cats
311 with FCV by the aerosol route (Hoover and Kahn, 1973, 1975; Ormerod et al., 1979).

312

313 The desquamated cells found in the alveolar lumen were mainly AM, admixed with a
314 few type II pneumocytes. These cells, both detached and, less frequently, attached to the
315 alveolar wall, were activated, as evidenced by their expression of MMP-9, a gelatinase (92
316 kDa gelatinase B) that digests collagen IV and thereby the basement membrane, and is
317 assumed to facilitate the inflammatory cell recruitment (Pardo et al., 1999; Kim et al., 2009).
318 In most cases with more extensive changes (i.e. severe URD and pneumonia), this cellular
319 reaction was associated with alveolar fibrin exudation, indicating that not only alveolar cells,
320 but also vascular endothelial cells were injured, leading to increased vascular permeability.
321 These vascular effects are typical of acute DAD and result from damage to the extracellular

322 matrix induced by, among other factors, MMP-9; consequently, DAD can be mediated by AM
323 alone (Gibbs et al., 1999; Gushima et al., 2001).

324

325 FCV pneumonia shares many histopathological features with the lungs of fatal human
326 avian influenza cases; both exhibit DAD, with an acute exudative phase and, later, a
327 proliferative phase (Nakajima et al., 2013), whereby type II pneumocyte hyperplasia is a
328 consequence of the initial epithelial and endothelial cell damage (Langloss et al., 1978a;
329 Myers et al., 1993).

330

331 Pulmonary FCV infection was either associated with URD or appeared to be the only
332 virally induced lesion in the respiratory tract, indicating that FCV reaches the lung by
333 inhalation of aerosols after natural infection, confirming that the experimental approach of
334 older studies was appropriate (Holzinger and Kahn, 1970; Kahn and Gillespie, 1971; Hoover
335 and Kahn, 1973, 1975; Love, 1975; Langloss et al., 1978a; Ormerod et al., 1979). The
336 pulmonary changes observed in the present study are similar to those described in
337 experimentally infected cats, apart from the initial neutrophil recruitment in the latter, which
338 might be due to the high viral dose administered (Holzinger and Kahn, 1970; Kahn and
339 Gillespie, 1971; Hoover and Kahn, 1973, 1975; Love, 1975; Langloss et al., 1978a).
340 However, in the lungs of human beings infected with avian influenza, substantial neutrophil
341 infiltration has been documented (Nakajima et al., 2013).

342

343 The lung lesions in the four VS-FCV cases (group 4) were histopathologically similar to
344 those in the other three groups. VS-FCV strains are highly virulent and have both a wider
345 target cell spectrum and more intense cytopathic effect than other FCV isolates (Radford et
346 al., 2007; Pesavento et al., 2008). In the lungs, this can result in infection and death of

347 respiratory epithelial cells, as indicated by the focal FCV infection and apoptotic loss of
348 bronchial epithelium observed in one cat in the present study.

349

350 In FCV pneumonia, the virus was mainly identified within AM. RNA-ISH to
351 demonstrate both positive and negative strand viral RNA showed that it is not only
352 phagocytosed by the AM, as suggested by previous in vitro studies (Langloss et al., 1978b),
353 but it also replicates in these cells. Similarly, we found that FCV infected both activated and
354 hyperplastic type II pneumocytes in the acute lesions and also replicated in those cells.
355 Hyperplastic type II pneumocytes could be a site for viral persistence in the lungs. Feline
356 junctional adhesion molecule A (fJAM-A), an immunoglobulin-like molecule that is
357 expressed in a wide range of feline cells, including epithelial and endothelial cells and
358 leucocytes (Makino et al., 2006; Ossiboff and Parker, 2007; Pesavento et al., 2011), mediates
359 FCV attachment and entry into cells. The selected cell tropism of most FCV strains, however,
360 is likely mediated by α 2,6-sialic acids, which are also responsible for the macrophage tropism
361 of murine noroviruses, which are also members of the Caliciviridae (Makino et al., 2006;
362 Ossiboff and Parker, 2007; Stuart and Brown, 2007). In contrast, VS-FCV might have an
363 altered receptor usage, which allows it to infect a wider range of cell types.

364

365 Our study provides strong evidence that FCV induces apoptosis in infected
366 macrophages and respiratory epithelial cells in vivo. This supports in vitro studies, which
367 demonstrated that FCV infection induces caspase activation, including caspase-3, which we
368 used to confirm cell death via apoptosis using IH (Sosnovtsev et al., 2003; Natoni et al.,
369 2006).

370

371 In a few cases, we found co-infection of FCV with FHV-1 or bacteria. FCV and FHV-1
372 co-infection of the upper respiratory tract is a known feature of URD and was recently found
373 in 9% of cats that tested positive for either virus in a cat population in Brazil (Henzel et al.,
374 2012). The presence of a concomitant bacterial infection with *Pasteurella multocida* or
375 *Mycoplasma* spp., both opportunistic pathogens that are part of the normal nasopharyngeal
376 bacterial population (Gaskell et al., 2012), are secondary and are likely **be** established after
377 DAD.

378

379 **Conclusions**

380 In this study, lung involvement was an infrequent, but relevant, feature of FCV-
381 induced URD. Acute FCV-induced lung lesions were consistent with DAD. AM were the
382 main viral target cells and the site of viral replication in the lung, and their infection was
383 associated with desquamation, activation and apoptosis.

384

385 **Conflict of interest statement**

386 None of the authors of this paper has a financial or personal relationship with other
387 people or organisations that could inappropriately influence or bias the content of the paper.

388

389 **Acknowledgements**

390 The authors wish to thank the technicians in the Histology Laboratory, Veterinary
391 Laboratory Services, School of Veterinary Sciences, for excellent technical support. Thanks
392 are due to Dr Carol Porter, University of Liverpool, for providing the peptide anti-FCV
393 antibody, and to Hanna-Kaisa Sihvo, University of Helsinki, Finland, Cinzia Benazzi,
394 University of Bologna, Italy, Marta Leon, Merial, Spain, and Gustavo Ramirez, Histovet,
395 Spain for providing relevant case material and allowing us to include it.

397 **References**

- 398 Bannasch, M.J., Foley, J.E., 2005. Epidemiologic evaluation of multiple respiratory
399 pathogens in cats in animal shelters. *Journal of Feline Medicine and Surgery* 7, 109-
400 119.
401
- 402 Battilani, M., Vaccari, F., Carelle, M.S., Morandi, F., Benazzi, C., Kipar, A., Dondi, F.,
403 Scagliarini, A., 2013. Virulent feline calicivirus disease in a shelter in Italy: A case
404 description. *Research in Veterinary Science* 95, 283-290.
405
- 406 Carter, M.J., Milton, I.D., Meanger, J., Bennett, M., Gaskell, R.M., Turner, P.C., 1992. The
407 complete nucleotide sequence of a feline calicivirus. *Virology* 190, 443-448.
408
- 409 Caswell, J.L., Williams, K.J., 2007. Respiratory System. In: Maxie, G.M. (Ed.). *Jubb,*
410 *Kennedy, and Palmer's Pathology of Domestic Animals*, 5th Edn. Saunders
411 Elsevier, Philadelphia, USA, pp. 523-653.
412
- 413 Clarke, I.N., Lambden, P.R., 1997. The molecular biology of caliciviruses. *Journal of General*
414 *Virology* 78, 291-301.
415
- 416 Coyne, K.P., Jones, B.R., Kipar, A., Chantrey, J., Porter, C.J., Barber, P.J., Dawson, S.,
417 Gaskell, R.M., Radford, A.D., 2006a. Lethal outbreak of disease associated with
418 feline calicivirus infection in cats. *Veterinary Record* 158, 544-550.
419
- 420 Coyne, K.P., Reed, F.C., Porter, C.J., Dawson, S., Gaskell, R.M., Radford, A.D., 2006b.
421 Recombination of feline calicivirus within an endemically infected cat colony.
422 *Journal of General Virology* 87, 921-926.
423
- 424 Coyne, K.P., Gaskell, R.M., Dawson, S., Porter, C.J., Radford, A.D., 2007. Evolutionary
425 mechanisms of persistence and diversification of a calicivirus within endemically
426 infected natural host populations. *Journal of Virology* 81, 1961-1971.
427
- 428 Dawson, S., Bennett, D., Carter, S.D., Bennett, M., Meanger, J., Turner, P.C., Carter, M.J.,
429 Milton, I., Gaskell, R.M., 1994. Acute arthritis of cats associated with feline
430 calicivirus infection. *Research in Veterinary Science* 56, 133-143.
431
- 432 Di Martino, B., Di Francesco, C.E., Meridiani, I., Marsilio, F., 2007. Etiological investigation
433 of multiple respiratory infections in cats. *New Microbiologica* 30, 455-461.
434
- 435 Dick, C.P., Johnson, R.P., Yamashiro, S., 1989. Sites of persistence of feline calicivirus.
436 *Research in Veterinary Science* 47, 367-373.
437
- 438 Gaskell, R.M., Dawson, S., Radford, A., 2012. Feline respiratory disease. In: Greene, C.E.
439 (Ed.). *Infectious Diseases of the Dog and Cat*, 4th Edn. Saunders Elsevier, St Louis,
440 Missouri, USA, pp. 151-162.
441

- 442 Geissler, K., Schneider, K., Truyen, U., 2002. Mapping neutralizing and non-neutralizing
443 epitopes on the capsid protein of feline calicivirus. *Journal of Veterinary Medicine B,*
444 *Infectious Diseases and Veterinary Public Health* 49, 55-60.
445
- 446 Gibbs, D.F., Shanley, T.P., Warner, R.L., Murphy, H.S., Varani, J., Johnson, K.J., 1999. Role
447 of matrix metalloproteinases in models of macrophage-dependent acute lung injury.
448 Evidence for alveolar macrophage as source of proteinases. *American Journal of*
449 *Respiratory Cell and Molecular Biology* 20, 1145-1154.
450
- 451 Gushima, Y., Ichikado, K., Suga, M., Okamoto, T., Iyonaga, K., Sato, K., Miyakawa, H.,
452 Ando, M., 2001. Expression of matrix metalloproteinases in pigs with hyperoxia-
453 induced acute lung injury. *European Respiratory Journal* 18, 827-837.
454
- 455 Henzel, A., Brum, M.C., Lautert, C., Martins, M., Lovato, L.T., Weiblen, R., 2012. Isolation
456 and identification of feline calicivirus and feline herpesvirus in Southern Brazil.
457 *Brazilian Journal of Microbiology* 43, 560-568.
458
- 459 Holzinger, E.A., Kahn, D.E., 1970. Pathologic features of picornavirus infections in cats.
460 *American Journal of Veterinary Research* 31, 1623-1630.
461
- 462 Hoover, E.A., Kahn, D.E., 1973. Lesions produced by feline picornaviruses of different
463 virulence in pathogen-free cats. *Veterinary Pathology* 10, 307-322.
464
- 465 Hoover, E.A., Kahn, D.E., 1975. Experimentally induced feline calicivirus infection: Clinical
466 signs and lesions. *Journal of the American Veterinary Medicine Association* 166,
467 463-468.
468
- 469 Hughes, D.J., Kipar, A., Leeming, G.H., Bennett, E., Howarth, D., Cummerson, J.A.,
470 Papoula-Pereira, R., Flanagan, B.F., Sample, J.T., Stewart, J.P., 2011. Chemokine
471 binding protein M3 of murine gammaherpesvirus 68 modulates the host response to
472 infection in a natural host. *PLoS Pathogens* 7, e1001321.
473
- 474 Hurley, K.F., Sykes, J.E., 2003. Update on feline calicivirus: New trends. *Veterinary Clinics*
475 *of North America: Small Animal Practice* 33, 759-772.
476
- 477 Hurley, K.E., Pesavento, P.A., Pedersen, N.C., Poland, A.M., Wilson, E., Foley, J.E., 2004.
478 An outbreak of virulent systemic feline calicivirus disease. *Journal of the American*
479 *Veterinary Medicine Association* 224, 241-249.
480
- 481 Johnson, R.P., 1992. Antigenic change in feline calicivirus during persistent infection.
482 *Canadian Journal of Veterinary Research* 56, 326-330.
483
- 484 Kahn, D.E., Gillespie, J.H., 1971. Feline viruses: Pathogenesis of picornavirus infection in the
485 cat. *American Journal of Veterinary Research* 32, 521-531.
486
- 487 Kahn, D.E., Hoover, E.A., Bittle, J.L., 1975. Induction of immunity to feline caliciviral
488 disease. *Infection and Immunity* 11, 1003-1009.
489
- 490 Kahn, D.E., Hoover, E.A., 1976. Feline caliciviral disease: Experimental immunoprophylaxis.
491 *American Journal of Veterinary Research* 37, 279-283.

492
493 Kim, J.Y., Choeng, H.C., Ahn, C., Cho, S.H., 2009. Early and late changes of MMP-2 and
494 MMP-9 in bleomycin-induced pulmonary fibrosis. *Yonsei Medical Journal* 50, 68-
495 77.
496
497 Kipar, A., May, H., Menger, S., Weber, M., Leukert, W., Reinacher, M., 2005. Morphologic
498 features and development of granulomatous vasculitis in feline infectious peritonitis.
499 *Veterinary Pathology* 42, 321-330.
500
501 Langloss, J.M., Hoover, E.A., Kahn, D.E., 1978a. Ultrastructural morphogenesis of acute
502 viral pneumonia produced by feline calicivirus. *American Journal of Veterinary*
503 *Research* 39, 1577-1583.
504
505 Langloss, J.M., Hoover, E.A., Kahn, D.E., Kniazeeff, A.J., 1978b. In vitro interaction of
506 alveolar macrophages and pneumocytes with feline respiratory viruses. *Infection and*
507 *Immunity* 20, 836-841.
508
509 Leeming, G., Meli, M.L., Cripps, P., Vaughan-Thomas, A., Lutz, H., Gaskell, R., Kipar, A.,
510 2006. Tracheal organ cultures as a useful tool to study felid herpesvirus 1 infection in
511 respiratory epithelium. *Journal of Virological Methods* 138, 191-195.
512
513 Love, D.N., Baker, K.D., 1972. Sudden death in kittens associated with a feline picornavirus.
514 *Australian Veterinary Journal* 48, 643.
515
516 Love, D.N., 1975. Pathogenicity of a strain of feline calicivirus for domestic kittens.
517 *Australian Veterinary Journal* 51, 541-546.
518
519 Makino, A., Shimojima, M., Miyazawa, T., Kato, K., Tohya, Y., Akashi, H., 2006. Junctional
520 adhesion molecule 1 is a functional receptor for feline calicivirus. *Journal of*
521 *Virology* 80, 4482-4490.
522
523 Mulugeta, S., Beers, M.F., 2006. Surfactant protein C: Its unique properties and emerging
524 immunomodulatory role in the lung. *Microbes and Infection* 8, 2317-2323.
525
526 Myers, J.L., Colby, T.V., Yousem, S.A., 1993. Common pathways and patterns of injury. In:
527 Dail, D.H., Hammar, S.P. (Eds). *Pulmonary Pathology*, 2nd Edn. Springer, New
528 York, USA, pp. 57-77.
529
530 Nakajima, N., Van Tin, N., Sato, Y., Thach, H.N., Katano, H., Diep, P.H., Kumasaka, T.,
531 Thuy, N.T., Hasegawa, H., San, L.T., et al., 2013. Pathological study of archival lung
532 tissues from five fatal cases of avian H5N1 influenza in Vietnam. *Modern Pathology*
533 26, 357-369.
534
535 Natoni, A., Kass, G.E., Carter, M.J., Roberts, L.O., 2006. The mitochondrial pathway of
536 apoptosis is triggered during feline calicivirus infection. *Journal of General Virology*
537 87, 357-361.
538
539 Ormerod, E., McCandlish, I.A., Jarrett, O., 1979. Diseases produced by feline caliciviruses
540 when administered to cats by aerosol or intranasal instillation. *Veterinary Record*
541 104, 65-69.

542
543 Ossiboff, R.J., Parker, J.S., 2007. Identification of regions and residues in feline junctional
544 adhesion molecule required for feline calicivirus binding and infection. *Journal of*
545 *Virology* 81, 13608-13621.
546

547 Pardo, A., Perez-Ramos, J., Segura-Valdez, L., Ramirez, R., Selman, M., 1999. Expression
548 and localization of TIMP-1, TIMP-2, MMP-13, MMP-2, and MMP-9 in early and
549 advanced experimental lung silicosis. *Annals of the New York Academy of Sciences*
550 878, 587-589.
551

552 Pedersen, N.C., Elliott, J.B., Glasgow, A., Poland, A., Keel, K., 2000. An isolated epizootic of
553 hemorrhagic-like fever in cats caused by a novel and highly virulent strain of feline
554 calicivirus. *Veterinary Microbiology* 73, 281-300.
555

556 Pesavento, P.A., MacLachlan, N.J., Dillard-Telm, L., Grant, C.K., Hurley, K.F., 2004.
557 Pathologic, immunohistochemical, and electron microscopic findings in naturally
558 occurring virulent systemic feline calicivirus infection in cats. *Veterinary Pathology*
559 41, 257-263.
560

561 Pesavento, P.A., Chang, K.O., Parker, J.S., 2008. Molecular virology of feline calicivirus.
562 *Veterinary Clinics of North America: Small Animal Practice* 38, 775-786.
563

564 Pesavento, P.A., Stokol, T., Liu, H., van der List, D.A., Gaffney, P.M., Parker, J.S., 2011.
565 Distribution of the feline calicivirus receptor junctional adhesion molecule A in
566 feline tissues. *Veterinary Pathology* 48, 361-368.
567

568 Poulet, H., Brunet, S., Leroy, V., Chappuis, G., 2005. Immunisation with a combination of
569 two complementary feline calicivirus strains induces a broad cross-protection against
570 heterologous challenges. *Veterinary Microbiology* 106, 17-31.
571

572 Povey, R.C., Johnson, R.H., 1971. A survey of feline viral rhinotracheitis and feline
573 picornavirus infection in Britain. *Journal of Small Animal Practice* 12, 233-247.
574

575 Radford, A.D., Bennett, M., McArdle, F., Dawson, S., Turner, P.C., Glenn, M.A., Gaskell,
576 R.M., 1997. The use of sequence analysis of a feline calicivirus (FCV) hypervariable
577 region in the epidemiological investigation of FCV related disease and vaccine
578 failures. *Vaccine* 15, 1451-1458.
579

580 Radford, A.D., Willoughby, K., Dawson, S., McCracken, C., Gaskell, R.M., 1999. The capsid
581 gene of feline calicivirus contains linear B-cell epitopes in both variable and
582 conserved regions. *Journal of Virology* 73, 8496-8502.
583

584 Radford, A.D., Dawson, S., Ryvar, R., Coyne, K., Johnson, D.R., Cox, M.B., Acke, E.F.,
585 Addie, D.D., Gaskell, R.M., 2003. High genetic diversity of the immunodominant
586 region of the feline calicivirus capsid gene in endemically infected cat colonies.
587 *Virus Genes* 27, 145-155.
588

589 Radford, A.D., Dawson, S., Coyne, K.P., Porter, C.J., Gaskell, R.M., 2006. The challenge for
590 the next generation of feline calicivirus vaccines. *Veterinary Microbiology* 117, 14-
591 18.

592
593 Radford, A.D., Coyne, K.P., Dawson, S., Porter, C.J., Gaskell, R.M., 2007. Feline calicivirus.
594 Veterinary Research 38, 319-335.
595
596 Radford, A.D., Addie, D., Belak, S., Boucraut-Baralon, C., Egberink, H., Frymus, T.,
597 Gruffydd-Jones, T., Hartmann, K., Hosie, M.J., Lloret, A., et al., 2009. Feline
598 calicivirus infection. ABCD guidelines on prevention and management. Journal of
599 Feline Medicine and Surgery 11, 556-564.
600
601 Schorr-Evans, E.M., Poland, A., Johnson, W.E., Pedersen, N.C., 2003. An epizootic of highly
602 virulent feline calicivirus disease in a hospital setting in New England. Journal of
603 Feline Medicine and Surgery 5, 217-226.
604
605 Schulz, B.S., Hartmann, K., Unterer, S., Eichhorn, W., Majzoub, M., Homeier-Bachmann, T.,
606 Truyen, U., Ellenberger, C., Huebner, J., 2011. Two outbreaks of virulent systemic
607 feline calicivirus infection in cats in Germany. Berliner und Münchener Tierärztliche
608 Wochenschrift 124, 186-193.
609
610 Scott, F.W., 1977. Evaluation of a feline viral rhinotracheitis-feline calicivirus disease
611 vaccine. American Journal of Veterinary Research 38, 229-234.
612
613 Sosnovtsev, S.V., Prikhod'ko, E.A., Belliot, G., Cohen, J.I., Green, K.Y., 2003. Feline
614 calicivirus replication induces apoptosis in cultured cells. Virus Research 94, 1-10.
615
616 Stuart, A.D., Brown, T.D., 2007. α 2,6-Linked sialic acid acts as a receptor for feline
617 calicivirus. Journal of General Virology 88, 177-186.
618
619 Tamura, K., Dudley, J., Nei, M., Kumar, S., 2007. MEGA4: Molecular Evolutionary Genetics
620 Analysis (MEGA) software version 4.0. Molecular Biology and Evolution 24, 1596-
621 1599.
622
623 Truyen, U., Addie, D., Belak, S., Boucraut-Baralon, C., Egberink, H., Frymus, T., Gruffydd-
624 Jones, T., Hartmann, K., Hosie, M.J., Lloret, A., et al., 1997. Calicivirus outbreak
625 with high mortality in a Missouri feline colony. Journal of Veterinary Diagnostic and
626 Investigation 9, 195-198.
627
628 Velasco, T., Hosie, M., Samman, A., Kipar, A., Thibault, J.-C., León, M., 2013. Feline
629 calicivirus associated virulent systemic disease (FCV-VSD): Report on the first
630 confirmed case in Madrid (Spain). Journal of Feline Medicine and Surgery 15, 9,
631 818-828.

632 **Table 1**

633 Relevant gross and histological findings for group 1: Cats with upper respiratory disease (URD) and pneumonia,
 634 involvement of feline calicivirus (FCV) confirmed by isolation of FCV from the lungs and
 635 immunohistochemistry (IH) for FCV antigen.
 636

Case	Breed	Age	Sex	Lung histopathology	Demonstration of FCV
1.1	ESH	11 years	F	Multifocal mild to moderate fibrin exudation and low numbers of AM/type II pneumocytes ^a in AL	IH: Scattered cells in AW (type II pneumocytes) and in AL (AM)
1.2	DSH	8 weeks	NK	Multifocal moderate to marked fibrin exudation and moderate numbers of often apoptotic ^b AM/type II pneumocytes with a few neutrophils in AL; bronchiolar lumen with similar content; moderate hyperaemia and perivascular oedema	IH: Moderate numbers of cells in AL, occasional cells in AW ISH (S, AS): Moderate number of cells in AL (IH, FHV: Negative)
1.3	DSH	12 weeks	F	Multifocal marked fibrin exudation and abundant AM/ type II pneumocytes in AL; bronchiolar lumen with similar content; diffuse fibrin exudation on pleura	IH: Low numbers of cells in AL ISH (S, AS): Low number of cells in AL
1.4	DSH	8 weeks	F	Multifocal moderate to marked fibrin exudation and abundant, occasionally apoptotic AM/type II pneumocytes in AL; moderate numbers of extravasated erythrocytes and erythrophagocytosis in AL; bronchioles with similar content and with focal loss and degeneration of epithelial cells and presence of macrophages	IH: Low to moderate numbers of cells in AL, some macrophages/degenerate epithelial cells in bronchiolar wall. ISH (S, AS): Low number of cells in AL
1.5	ESH	6 years	MN	Multifocally, low to moderate numbers of AM/type II pneumocytes in AL; marked alveolar oedema and occasional extravasated erythrocytes in AL	IH: Low numbers of cells in AL (IH, FHV: Positive, tongue; negative, lung)
1.6	MC	1 week	M	Multifocal mild to moderate alveolar fibrin exudation and desquamation of abundant, often apoptotic AM and type II pneumocytes; bronchioles with similar content	IH: Moderate numbers of desquamated cells in alveoli ISH (S, AS): Scattered cells in alveolar lumen
1.7	MC	12 weeks	F	Multifocal moderate fibrin exudation and abundant, often apoptotic AM and type II pneumocytes in AL, in focal area with extensive fibrin exudation and necrosis, and neutrophil infiltration	IH: Moderate numbers of cells in AL; cell free viral antigen in area with necrosis (IH, FHV: Negative)
1.8	DSH	4 weeks	M	Multifocal extensive fibrin exudation and abundant, often apoptotic AM/type II pneumocytes in AL, mild erythrocyte extravasation in AL.	IH: Scattered desquamated cells in AL

637

638 ESH, European shorthair; DSH, Domestic shorthair; BSH, British shorthair; MC, Maine Coon; F, female; M, male; N, neutered; NK, not
 639 known; AL, alveolar lumina; AM, alveolar macrophages; AS, anti-sense probe; AW, alveolar wall; FHV, feline herpesvirus type 1; ISH,
 640 RNA-in situ hybridisation; S, sense probe.

641 ^a AM/type II pneumocytes, numerous CD18 positive AM and scattered individual SP-C positive type II pneumocytes.

642 ^b Apoptosis/apoptotic: confirmed by IH (cleaved caspase-3 positive).

643

644 **Table 2**

645 Relevant gross and histological findings for group 2: Cats with upper respiratory disease (URD) and pneumonia,
 646 involvement of feline calicivirus (FCV) confirmed by immunohistochemistry (IH) for FCV antigen.
 647

Case	Breed	Age	Sex	Lung histopathology	Demonstration of FCV
2.1	DSH	12 weeks	M	Multifocal moderate fibrin exudation and very abundant AM/type II pneumocytes in AL; bronchioles with similar content	IH: Low number of cells in AL and in bronchiolar lumina
2.2	DSH	4 years	F	Multifocal mild fibrin exudation and moderate numbers of AM/type II pneumocytes in AL	IH: Scattered cells in AL (IH, FHV: negative)
2.3	DSH	8 weeks	F	Multifocal extensive fibrin exudation and moderate to large numbers of AM/type II pneumocytes in AL	IH: Several cells in AL ISH (S, AS): Several cells in AL (IH, FHV: Negative)
2.4	Oriental	12 weeks	F	Multifocal low to moderate numbers of AM/type II pneumocytes in AL	IH: Several cells in AL
2.5	DSH	3.5 years	MN	Multifocal moderate fibrin exudation and abundant, often apoptotic AM/type II pneumocytes in AL; mild focal type II pneumocyte hyperplasia; moderate interstitial macrophage infiltration	IH: Moderate to high number of cells in AW (type II pneumocytes). (IH, FHV: Negative)
2.6	DSH	11 weeks	F	Multifocal moderate fibrin exudation and moderate numbers of occasionally apoptotic AM/type II pneumocytes in AL; moderate amount of lymphocytes and plasma cells in interstitium	IH: Moderate number of cells in AL (IH, FHV: Negative)

648

649 DSH, Domestic Shorthair; F, female; M, male; N, neutered; AM, alveolar macrophages; AW, alveolar wall; AL, alveolar lumina; ISH, RNA-
 650 in situ hybridisation; S, sense probe; AS, anti-sense probe; FHV, Feline herpesvirus type 1.

651 **Table 3**

652 Relevant gross and histological findings for group 3: Cats without upper respiratory disease (URD) and
 653 histological findings consistent with feline calicivirus (FCV) pneumonia, involvement of FCV confirmed by
 654 immunohistochemistry (IH) for FCV antigen.

655

Case	Breed	Age	Sex	Primary disease	Lung histopathology	Demonstration of FCV
3.1	DSH	8 weeks	M	Feline parvovirus enteritis	Multifocal fibrin exudation and abundant, partly apoptotic AM/type II pneumocytes; mild to moderate multifocal type II pneumocyte hyperplasia; moderate interstitial macrophage infiltration	IH: Moderate number of cells in AL ISH (S, AS): Several cells in AL
3.2	BSH	1 year	MN	Feline parvovirus enteritis	Multifocally, low numbers of partly apoptotic AM/type II pneumocytes in AL	IH: Scattered cells in AW (type II pneumocytes?) or in AL

656

657 DSH, Domestic shorthair; BSH, British shorthair; M, male; N, neutered; AM, alveolar macrophages; AW, alveolar wall; AL, alveolar
 658 lumina; ISH, RNA-in situ hybridisation; S, sense probe; AS, anti-sense probe.

659 **Table 4**

660 Relevant gross and histological findings for group 4: Cats with virulent systemic feline calicivirus (FCV) and
 661 demonstration of FCV antigen in the lungs by immunohistochemistry (IH)

662

Case	Breed	Age	Sex	Lung histopathology	Demonstration of FCV
4.1 ^a	DSH	3 years	FN	Multifocal desquamation of low numbers of AM/type II pneumocytes	Isolation and PCR (oropharyngeal swab); PCR IH: Several cells in AL
4.2 ^b	DSH	10 years	MN	Multifocally, low numbers of AM/type II pneumocytes in AL	FCV (oropharyngeal swab, tissues); PCR IH: Several cells in AL
4.3	DSH	6 weeks	NK	Multifocal marked fibrin exudation and moderate numbers of partly apoptotic AM/type II pneumocytes in AL; focal extensive apoptosis and loss of bronchiolar epithelial cells	IH: Moderate number of intact and apoptotic cells and cell free in AL ISH (S, AS): Moderate number of (apoptotic) cells in AL and focally numerous (apoptotic) bronchiolar epithelial cells
4.4 ^c	DSH	Adult	M	Multifocally, low numbers of AM/type II pneumocytes in AL	Isolation (spleen); PCR; IH: A few cells in AL

663

664 DSH, Domestic shorthair; F, female; M, male; N, neutered; NK, not known; AM, alveolar macrophages; AL, alveolar lumina; ISH, RNA-in
 665 situ hybridisation; S, sense probe; AS, anti-sense probe

666 ^a Coyne et al. (2006).

667 ^b Battilani et al. (2013).

668 ^c Velasco et al. (2013).

669 **Table 5**

670 Antibodies, detection method and antigen retrieval for immunohistochemistry.

671

Antibody	Source	Antigen retrieval	Detection method
Rabbit anti-FCV capsid	University of Liverpool (Coyne et al., 2006)	CB pH 6.0, 96 °C	PAP
Mouse anti-FCV (clone FCV2-16)	Custom Monoclonals International	CB pH 6.0, 96 °C	PAP
Mouse anti-FHV (clone FHV5)	Custom Monoclonals International	None	PAP
Mouse anti-SP-C (clone FL-197)	Santa Cruz Biotechnology	None	PAP
Rabbit anti-cleaved caspase 3	Cell Signaling	CB pH 6.0, 96 °C	PAP
Mouse anti-feline CD18 (clone FE3.9F2)	Leukocyte Antigen Biology Laboratory (University of California)	Bacterial protease	HP (Envision; Dako)
Mouse anti-human MMP-9 (clone IIA5)	NeoMarkers	CB pH 6.0, 96 °C	PAP

672

673 FCV, feline calicivirus; FHV, feline herpesvirus; SC, surfactant protein; MMP, matrix metalloproteinase; CB, citrate buffer; PAP, peroxidase

674 anti-peroxidase method; HP, horseradish peroxidase method.

675

676 **Figure legends**

677

678 Fig.1. Histological features of feline calicivirus (FCV)-associated lung lesions. (A) Cat with
679 upper respiratory disease (URD) and isolation of FCV from the lung (cat 1.2). Variable
680 numbers of desquamated alveolar macrophages (arrows) and scattered neutrophils and small
681 amounts of fibrin (arrowhead) are present in alveolar lumina. Bar = 20 μ m. (B) Cat with URD
682 and immunohistochemical confirmation of FCV infection (cat 2.5). Alveoli contain variable
683 numbers of desquamated alveolar macrophages (arrows) and a few extravasated erythrocytes.
684 Type II pneumocytes (arrowheads) often appear activated. Bar = 20 μ m. (C) Cat without
685 URD, but with immunohistochemical confirmation of FCV infection (cat 3.1). Apart from the
686 presence of fibrin and desquamated cells in alveolar lumina (arrowhead), moderate type II
687 pneumocyte hyperplasia (arrows) is seen in several alveoli. Bar = 20 μ m. (D) Cat with virulent
688 systemic FCV (cat 4.3). Alveoli contain abundant fibrin and several apoptotic alveolar
689 macrophages (arrowheads). The bronchiole exhibits focal apoptotic loss of respiratory
690 epithelial cells (arrow). Bar = 20 μ m. Haematoxylin and eosin staining.

691

692 Fig. 2. Immunohistochemical characterisation of feline calicivirus (FCV)-associated lung
693 lesions. (A) Cat with upper respiratory disease (URD) and isolation of FCV from the lung (cat
694 1.2). Expression of CD18 is seen in the vast majority of desquamated cells, which can be
695 identified as alveolar macrophages. Horseradish peroxidase method. Bar = 20 μ m. (B, C) Cat
696 with URD and immunohistochemical confirmation of FCV infection (cat 2.5). (B) Staining
697 for surfactant protein-C identifies type II pneumocytes (arrowheads), either attached to the
698 alveolar wall or, occasionally, desquamated. Peroxidase anti-peroxidase method. Bar = 20
699 μ m. (C) MMP-9 expression is seen in both desquamated alveolar macrophages (arrows) and
700 activated type II pneumocytes (arrowhead). Peroxidase anti-peroxidase method. Bar = 10 μ m.

701 (D) Cat without URD and immunohistochemical confirmation of FCV infection (cat 3.1).
702 Staining for cleaved caspase-3 confirms that numerous desquamated cells in alveolar lumina
703 undergo apoptosis (arrows). Peroxidase anti-peroxidase method. Bar = 20 μ m. Papanicolaou's
704 haematoxylin counterstain.

705

706 Fig.3. Expression of feline calicivirus (FCV) antigen in FCV-associated lung lesions. (A) Cat
707 with upper respiratory disease (URD) and isolation of FCV from the lung (cat 1.2). Numerous
708 desquamated alveolar macrophages (arrows) and scattered type II pneumocytes in the alveolar
709 wall express viral antigen. Bar = 20 μ m. (B) Cat with URD and immunohistochemical
710 confirmation of FCV infection (cat 2.5). Apart from desquamated alveolar macrophages
711 (arrows), a few type II pneumocytes attached to the alveolar wall (arrowheads) express viral
712 antigen. Bar = 10 μ m. (C) Cat without URD and immunohistochemical confirmation of FCV
713 infection (cat 3.1). Numerous, often apoptotic cells in alveolar lumina (arrows) express viral
714 antigen. Bar = 20 μ m. Inset: FCV antigen expression in an activated type II pneumocyte. Bar
715 = 10 μ m. (D) Cat with VS-FCV (cat 4.3). Alveoli contain numerous cells, often apoptotic
716 (arrows), that express viral antigen. A bronchiole exhibits focal loss and apoptosis of
717 respiratory epithelial cells that exhibit strong viral antigen expression (arrow heads).
718 Numerous FCV antigen positive degenerate cells are also found in the bronchiolar lumen
719 (BL). Bar = 20 μ m. Peroxidase anti-peroxidase method. Papanicolaou's haematoxylin
720 counterstain.

721

722 Fig. 4. Demonstration of feline calicivirus (FCV) genome and replication in FCV-associated
723 lung lesions. (A) Cat with upper respiratory disease (URD) and isolation of FCV from the
724 lung (cat 1.2). Several, partly apoptotic desquamated cells in the alveolar lumen show a
725 positive signal (arrows) for positive strand viral RNA (top); a few also express negative

726 strand, replicative intermediate stage viral RNA (bottom). Bars = 20 μ m. (B, C) Cat with
727 URD and immunohistochemical confirmation of FCV infection (cat 2.5). (B) Desquamated
728 cells in the alveolar lumen show a positive signal (arrows) for positive strand viral RNA (top).
729 Activated type II pneumocytes exhibit a signal for negative strand, replicative intermediate
730 stage viral RNA (bottom); V, vessel. Bars = 10 μ m. (C) Focal areas with type II pneumocyte
731 hyperplasia, with abundant signal for negative strand, replicative viral RNA (binding of sense
732 probe) in type II cells (arrows). Bar = 20 μ m. (D) Cat without URD or immunohistochemical
733 confirmation of FCV infection (cat 3.1). Alveoli contain numerous cells, often apoptotic
734 (arrows), that express negative strand, replicative viral RNA (arrows), detected by binding of
735 the sense probe. A bronchiole exhibits focal loss and apoptosis of respiratory epithelial cells
736 that exhibit strong signals for negative strand, replicative viral RNA (arrowheads). BL,
737 bronchiolar lumen. Bar = 10 μ m. RNA-in situ hybridisation; NBT/BCIP. Papanicolaou's
738 haematoxylin counterstain.

Figure 1
[Click here to download high resolution image](#)







Figure 2
[Click here to download high resolution image](#)







Figure 3
[Click here to download high resolution image](#)












Figure 4
[Click here to download high resolution image](#)



Revision Note

We thank the editor and reviewers for their feedback on our manuscript and have carefully attended all their comments.

Editor's comment:

We thank the editor for editing our manuscript. From the editor's feedback, the main issue was the following:

Your manuscript is currently 4134 words long. Can you please try to revise the word count down so that it is closer to the 3000 word limit for Original Articles in TVJ?

Response: We have carefully gone through the manuscript again and have made some changes to shorten the text. However, the reviewers requested a few changes that then added further words to the manuscript. At present, it has a length (introduction to conclusions) of 3,902 words. We feel that further cuts would reduce the value of the manuscript but are happy to undertake another attempt if the editor wishes us to and is happy with a less thorough report and discussion.

Reviewer #1:

This is a well conducted useful study which sheds new light on the role of FCV in the lungs of naturally infected cats.

Response: We thank the reviewer for the positive comment.

line 4 - can the authors's justify the use of the word "mediate" in the title

Response: We agree with the reviewer that "mediate" might not be the best term to describe the role of alveolar macrophages in FCV-associated pneumonia and have therefore changed the title to "Alveolar macrophages are the main target cells in feline calicivirus-associated pneumonia" in the hope that the reviewer will agree with this title.

Line 28 - there are some reports of FCV-like viruses in dogs (Martella V, Pratelli A, Gentile M, Buonavoglia D, Decaro N, Fiorente P, Buonavoglia C (2002). Analysis of the capsid protein gene of a feline-like calicivirus isoalted from a dog. Veterinary Microbiology, 85:315-322.)

Response: In order to avoid any discussion about the host specificity, in particular in light of the publication mentioned by the reviewer, we have taken out the words "host specific".

Line 36 - VS in full Line 64 - don't need both "Caliciviridae" and "family"

Response: The text has been shortened and this text passage been deleted.

Line 68 - UDR

Response: The text has been changed accordingly.

Line 72 - C and E do not encode proteins, rather part of a protein

Response: We are grateful to the reviewer for pointing this out and have changed the text accordingly.

Line 188 - relatively conserved

Response: The text has been changed accordingly.

Line 735 - don't understand the "B, C" in the middle of this line.

Response: The “B, C.” refers to the subsequent text, meaning that Fig. 4B and C are from a “Cat with URD and immunohistological confirmation of FCV infection (case No. 2.5).” We believe that this is clear enough.

Line 308 - this conclusion seems unproven. Yes you have lesions in a dead cat. But that does not mean the lesions were associated with the cause of death. Apologies if I am missing something.

Response: The text has been changed to make the conclusion more understandable. For this purpose, we have again mentioned the severity of the pulmonary lesions (acute alveolar damage) which can alone be responsible for the animals’ death (lines 302 - 304 in the revised manuscript).

Line 372 - don't need to repeat the (Langloss et al., 1978b),

Response: The text has been changed accordingly.

Line 374 - persistence. This got me thinking. I would be interested in the authors' thoughts on what they would see if they were able to carry out their analyses on a recovered cat. Perhaps some of the staining they see represents "normal" lung. Perhaps the authors should comment on the need to analyse such cases in subsequent studies, as an additional control.

Response: This is an interesting point. The presence of hyperplastic type II pneumocytes in some animals indicates recovery of the lungs from initial FCV induced alveolar epithelial cell damage. The fact that viral RNA was found in occasional hyperplastic type II cells indicates that the virus can persist in these cells. However, with further recovery, these cells would further differentiate, mainly into functional type I cells, to ensure effective gas exchange. It is unlikely that these fully differentiated cells would still carry FCV, and if they did, in amounts high enough to be detected by RNA-ISH. The more sensitive PCR would not help much, since it would not allow identification of infected cells. Therefore, this question could only be addressed in a large experimental study, which would be extremely difficult to realise, at least in Europe.

Line 382/3 - don't need both family and Coronviridae

Response: The word “family” has been deleted.

Line 387 - have you formally confirmed? You have shown apoptosis. You have shown FCV infection. But you can't prove a link between the two. The figure 2d legend has it about right. Or perhaps I have missed the logic. I think you can say you have provided further evidence, this time in vivo, for

Response: The staining of consecutive sections demonstrates FCV and the apoptosis marker in the same lesion and thereby group of cells, which we consider as sufficient to use the term “confirm”. However, since we have not performed double staining, we of course did not show both features in the same cell. Therefore, the statement has been toned down (line 376 in the revised manuscript).

Line 393-398 - Possibly delete this last paragraph.

Response: We have decided to keep the text.

Line 405 - again, possibly delete the sentence relating to immunosuppressed cats.

Response: The sentence has been deleted.

Figure 2 legend may be made easier to follow by starting each section with the name of the antigen target. This reviewer found it hard to decipher.

Response: The text has been amended to provide information on the antigens that are detected at the beginning of each sentence on the relevant photo.

Reviewer #2:

In this study the involvement of FCV infection in pulmonary lesions in cats with natural respiratory disease was determined. So far mainly data from experimental infections are known which may not represent the type and extent of lesions found in naturally infected cats. Therefore, this study adds to our knowledge of the pathogenesis of FCV infection in domestic cats.

The study was done with a selected number of cats in which pulmonary involvement was already evidenced by virus isolation or virus antigen detection by immunohistochemical staining. Several genetic and immunological tools were used to identify the type of cells and the presence of viral antigen and/or viral replication. These tools and techniques provide sufficient information to draw the conclusions about the type and extent of lung lesions. There are some ambiguities regarding materials and methods that need to be addressed. Also some of the results need to be clarified.

Comments

- Four different groups of cats were included in the study. The second group consists of cats that had URD and pneumonia in which FCV involvement was evidenced only by immunohistology. From the M&M paragraph it is not clear if virus isolation was not performed or was performed but unsuccessful. In the results section authors state that FCV involvement was confirmed by immunohistology alone, which does not exclude that virus isolation was attempted. Only when reading the discussion it becomes clear that virological examination had not been undertaken.

Response: We agree with the reviewer; the text in M&M was ambiguous. We have amended it to clarify that virus culture was only undertaken in animals of group 1 (lines 130 and 131 in the revised manuscript).

- Besides staining for FCV antigen some samples were stained for FHV as well. It is not clear why only a selected number of cases were stained for FHV and which criteria were used to decide whether staining was performed or not. This information should be included.

Response: The immunohistology for FHV was done to exclude that FHV played a role in the lung lesions. It was therefore mainly done in group 2, where virus culture was not performed, which itself ruled out FHV infection of the lung when negative (Group 1). We have provided information on this in the M&M section (lines 151-153 in the revised manuscript).

- In cats from group 1, one case (No. 1.5) was shown to exhibit co-infection with FHV and FCV. However FHV staining was only performed in 3 out of 8 cats. The relevance of this finding should be discussed knowing that not all cats were screened for the presence of FHV (see also previous comment). Also the conclusion that co-infection was found in a few cases (discussion, last paragraph) seems of little value if not all samples were tested.

Response: As mentioned above, immunohistology for FHV was performed in the lungs to confirm that only FCV was involved. We consider this as relevant in the cats with FCV pneumonia in which virus culture had not been performed (group 2). We have tried to make this clearer in the text (results sections: lines 254/255).

- Staining for FCoV was only performed in 2 cases (based on the information in Table 1). The reason for performing this staining only in these 2 cases is not discussed. This cannot be concluded based on the histological information given in table 1.

Response: We did undertake FCoV immunohistologie in just a few cases, as a diagnostic panel that had been decided upon at the time of necropsy. However, we agree with the reviewer that this does not add anything to the manuscript and have therefore deleted all mentioning of the FCoV immunohistology, since FIP was not a differential diagnosis in any of these cases.

- Negative controls for the in situ hybridization are important to proof the specificity of the reactions. Information on the negative controls used in the in situ hybridization is lacking. These should be included and discussed.

Response: Information on the negative controls for ISH is now provided (lines 209/201 in the revised manuscript).

- In the results section authors refer to the occasional extravasation of erythrocytes into the alveolar lumen (fig 1B,C). This is not mentioned in the legend of the figure and also not indicated within the figure.

Response: Erythrocyte extravasation into the alveolar lumen is obvious in particular in Fig. 1B. A reference to this has now been included into the figure legend and the text been changed accordingly.

A few typos .

Introduction Line 68: self limiting UDR; should be: URD

Response: The text has been changed accordingly.

Introduction line 100 "into the aleolar lumen": change to: alveolar

Response: The text has been changed accordingly.

Discussion, line 383; Coronviridae: change to Coronaviridae

Response: The text has been changed accordingly.

We hope that the revised manuscript will now be acceptable for publication in The Veterinary Journal.

Sincerely,

Anja Kipar